PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Rimegepant - Migraine (acute)
PAD Profile : Rimegepant - Migraine (acute)
Keywords :
Acute migraine, migraine treatment, calcitonin gene-related peptide inhibitors, CGRP antagonists
Brand Names Include :
Vydura
Traffic Light Status
Status 1 of 1.
Status :
Green
Formulations :
- Oral lyophilisates
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Guidelines
No guidelines returned.
Other Drugs
- Naratriptan hydrochloride
- Sumatriptan succinate
- Zolmitriptan
- Frovatriptan
- Almotriptan
- Eletriptan
- Rizatriptan
- Melatonin
- Analgesics with anti-emetics
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
07 February 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves rimegepant for the acute treatment of Migraine with or without aura in adults in line with NICE TA919.
A GREEN traffic light status has been agreed.
Treatment with rimegepant for acute migraine is recommended by NICE, only if for previous migraines:
- at least 2 triptans were tried and these did not work well enough or
- triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.
Patients receiving 8 or more tablets per month should be considered for preventative treatment.
Associated BNF Codes
04. Central Nervous System
04.07.04. Antimigraine drugs